Sonlicromanol
drugOn this page
Also known as Kh-176Kh176
Summary
Sonlicromanol (CHEMBL4802153) is a phase-3 clinical-stage small molecule.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- Clinical trials: 6
- Chemistry: 332.4 Da · C19H28N2O3
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4802153 |
| Name | Sonlicromanol |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | no |
| PubChem CID | 72710875 |
| Molecular formula | C19H28N2O3 |
| Molecular weight | 332.4 |
| InChIKey | LZYWLEPSQNXESC-KUHUBIRLSA-N |
SMILES: CC1=C(C2=C(CC[C@@](O2)(C)C(=O)N[C@@H]3CCCNC3)C(=C1O)C)C
IUPAC name: (2S)-6-hydroxy-2,5,7,8-tetramethyl-N-[(3R)-piperidin-3-yl]-3,4-dihydrochromene-2-carboxamide
Also known as: Kh-176, Kh176, Sonlicromanol, SONLICROMANOL
Patent coverage: 36 distinct patent families (72 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 65 (90%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
0 indications (0 at ChEMBL trial phase 4).
Clinical trials
Total trials: 6.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 4 |
| PHASE3 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06451757 | PHASE3 | RECRUITING | KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases |
| NCT07298005 | PHASE2 | RECRUITING | Sonlicromanol in Post-COVID |
| NCT02909400 | PHASE2 | COMPLETED | The KHENERGY Study |
| NCT04165239 | PHASE2 | COMPLETED | The KHENERGYZE Study |
| NCT04846036 | PHASE2 | SUSPENDED | The KHENERGYC Study |
| NCT02544217 | PHASE1 | COMPLETED | A Dose-escalating Clinical Trial With KH176 |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.